Ovid Therapeutics Inc. (OVID) Stock Price & Analysis

Ovid Therapeutics Inc. (OVID) closed at USD 2.45 on Wednesday, October 28, 2026, up 8.41% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 2.26; the Oct 28, 2026 session ranged USD 2.21–2.5 on volume of 2,052,841 shares. Market capitalization is $478.48M, with a 52-week range of USD 1.18–3.11 (NCM). Source: Nexqual, retrieved October 29, 2026 at 01:13 UTC.

Also available as compact Markdown for AI agents: nexqual.com/OVID.md

Key facts (OVID)

• Last four reported quarters (through Jun 30, 2026): revenue $1.6M, net income -$34.5M (-2178.9% margin) (SEC filings).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (13 analysts), mean target USD 6.4 (range 4–9).
• Total return with dividends: 1Y +55.9% vs S&P 500 +13.2%; 5Y -27.9% vs S&P 500 +79.8%.
• Next earnings: 2026-11-11, EPS estimate USD -0.08, revenue estimate $26K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OVID)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (OVID)

P/S 302.3x · P/B 2.3x · Earnings yield -7.21%

Analysts (OVID)

Consensus Buy (mean 2.00 on a 1–5 scale), 13 analysts; mean target USD 6.4 (low 4, high 9).

Rating changes, last 120 days:

Total return (dividends reinvested) (OVID)

OVID earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

OVID recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

OVID suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 18, 2026.

OVID company outlook (results filed Mar 18, 2026)

• “Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses.”
• “Findings confirm OV329 penetrates the brain, engages the target, and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitter.”
• “In parallel, the Company is advancing plans for a Phase 2 randomized, placebo-controlled trial, which is expected to evaluate two dose levels and determine seizure reduction efficacy in people living with treatment-resistant FOS.”
• “Ovid is engaged in regulatory conversations and currently anticipates initiating the Phase 2 study in the second quarter of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

OVID analyst estimates and revisions

OVID options: expected move

Options price a move of about ±24.9% (±$0.60) by Nov 20, 2026, which includes earnings on Nov 11, 2026. Over the last 8 reports the stock moved ±7.1% on average.

30-day implied volatility 119.7% vs 64.5% realized over the last 30 trading days. Put/call ratio (volume) 2.2. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 01:13 UTC)

Technical Analysis (OVID)

Nexqual's technical model rates OVID "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 29, 2026 at 01:13 UTC.

Analyst Ratings (OVID)

Wall Street analysts rate OVID "Buy" based on 13 analysts, with a mean price target of USD 6.4 (range USD 4–9), per Nexqual as of October 29, 2026 at 01:13 UTC.

Earnings (OVID)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 01:13 UTC.

Financials & Fundamentals (OVID)

Source: Nexqual, October 29, 2026 at 01:13 UTC.

Financial Health Score (OVID)

Nexqual rates Ovid Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 01:13 UTC.

Ownership (OVID)

Source: Nexqual, October 29, 2026 at 01:13 UTC.

Leadership (OVID)

Ovid Therapeutics Inc. is led by Margaret Alexander, CEO, President & Director, per Nexqual as of October 29, 2026 at 01:13 UTC.

Major Backers & Investors (OVID)

Notable institutional backers of Ovid Therapeutics Inc. include Jupiter Topco LLC, Eventide Asset Management LLC, RA Capital Management, L.P., according to Nexqual as of October 29, 2026 at 01:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 01:13 UTC.

From Ovid Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Approximately 50 million people globally live with epilepsy, including an estimated three million adults and half a million children in the United States.
• Today, we are one of the few companies that has researched and developed three distinct MoAs to target seizures and we believe we are the only company that holds a portfolio of direct activators of KCC2.
• Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future drug candidates, novel discoveries, product development technologies and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing upon our proprietary rights.
• We also rely on trademarks, trade secrets, copyright protection, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.

Partnerships

• We also entered into a collaboration agreement with Gensaic (the "Gensaic Collaboration Agreement") to potentially develop up to three genetic medicines for neurological indications of interest to us, harnessing Gensaic's proprietary tissue-selective intracellular delivery platform.
• In March 2022, we entered into an exclusive patent license agreement with Marinus Pharmaceuticals, Inc. ("Marinus") ("Marinus License Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
• We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States or any other applicable jurisdiction.
• We may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential profitability of our drug candidates.
• Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 01:13 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt